Nitrophenyl derivatives as aldose reductase inhibitors. 2002

Luca Costantino, and Anna Maria Ferrari, and Maria Cristina Gamberini, and Giulio Rastelli
Dipartimento di Scienze Farmaceutiche, Università di Modena e Reggio Emilia, Via Campi 183, 41100 Modena, Italy. costantino.luca@unimo.it

Nitrophenyl derivatives were recently discovered as a new class of ALR2 inhibitors by means of docking and database screening of the National Cancer Institute database of organic molecules. The nitro group was predicted to bind to the Tyr48 and His110 active site residues of the enzyme, the site where acidic ALR2 inhibitors such as carboxylic acids bind in their anionic form. Given the novelty of these compounds, we decided to expand their structure-activity relationships by synthesizing and testing a series of derivatives and the corresponding compounds having a carboxylic group instead of the nitro moiety; the results obtained were rationalized by means of docking and molecular dynamics simulations. On the whole there is an agreement between inhibitory data and the results of molecular modeling experiments, supporting the hypothesized binding mode of these compounds.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009596 Nitrophenols PHENOLS carrying nitro group substituents. Nitrophenol
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002264 Carboxylic Acids Organic compounds containing the carboxy group (-COOH). This group of compounds includes amino acids and fatty acids. Carboxylic acids can be saturated, unsaturated, or aromatic. Carboxylic Acid,Acid, Carboxylic,Acids, Carboxylic
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006860 Hydrogen Bonding A low-energy attractive force between hydrogen and another element. It plays a major role in determining the properties of water, proteins, and other compounds. Hydrogen Bonds,Bond, Hydrogen,Hydrogen Bond
D000449 Aldehyde Reductase An enzyme that catalyzes reversibly the oxidation of an aldose to an alditol. It possesses broad specificity for many aldoses. EC 1.1.1.21. Aldose Reductase,Aldose Reductase Ia,Aldose Reductase Ib,Erythrose Reductase,Xylose Reductase,Reductase Ia, Aldose,Reductase Ib, Aldose,Reductase, Aldehyde,Reductase, Aldose,Reductase, Erythrose,Reductase, Xylose
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Luca Costantino, and Anna Maria Ferrari, and Maria Cristina Gamberini, and Giulio Rastelli
April 2002, Journal of enzyme inhibition and medicinal chemistry,
Luca Costantino, and Anna Maria Ferrari, and Maria Cristina Gamberini, and Giulio Rastelli
January 2006, Medicinal chemistry (Shariqah (United Arab Emirates)),
Luca Costantino, and Anna Maria Ferrari, and Maria Cristina Gamberini, and Giulio Rastelli
January 2016, Journal of enzyme inhibition and medicinal chemistry,
Luca Costantino, and Anna Maria Ferrari, and Maria Cristina Gamberini, and Giulio Rastelli
October 2020, Bioorganic & medicinal chemistry,
Luca Costantino, and Anna Maria Ferrari, and Maria Cristina Gamberini, and Giulio Rastelli
May 2014, Bioorganic & medicinal chemistry letters,
Luca Costantino, and Anna Maria Ferrari, and Maria Cristina Gamberini, and Giulio Rastelli
February 2015, Chemical biology & drug design,
Luca Costantino, and Anna Maria Ferrari, and Maria Cristina Gamberini, and Giulio Rastelli
June 2014, European journal of medicinal chemistry,
Luca Costantino, and Anna Maria Ferrari, and Maria Cristina Gamberini, and Giulio Rastelli
December 2022, Journal of molecular recognition : JMR,
Luca Costantino, and Anna Maria Ferrari, and Maria Cristina Gamberini, and Giulio Rastelli
January 1992, Journal of diabetes and its complications,
Luca Costantino, and Anna Maria Ferrari, and Maria Cristina Gamberini, and Giulio Rastelli
May 2012, ChemMedChem,
Copied contents to your clipboard!